FDA Determines Regulatory Review Period for VALCYTE Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially set a regulatory review period for VALCYTE, a human drug product, following a patent extension application submitted to the Director of Patents and Trademarks at the US Department of Commerce.